Selection of second-line tyrosine kinase inhibitor (TKI) in chronic myeloid leukemia (CML) is largely guided by kinase domain (KD) mutations in BCR::ABL1; however, a substantial subset of imatinib-resistant cases (~ 40%) lack targetable KD alterations, limiting therapeutic stratification. Given the critical role of the Src homology 2 (SH2) and SH3 domains in regulating BCR::ABL1 activity, we investigated regulatory domain mutations in a cohort of CML with clinically-validated front-line imatinib resistance. Deep sequencing identified a de novo mutation pair, located in SH2 (Y167H) and SH3 (T117P) domain, in 16% cases. Following this, structure-guided molecular dynamics simulations indicated this mutation pair to destabilize the imatinib-compatible BCR::ABL1 conformation, resulting in reduced inhibitor engagement. Likewise, in vitro and in vivo experiments corroborated this non-responsiveness to imatinib. In contrast, computational and experimental analyses identified dasatinib as an effective second-line agent, restoring drug sensitivity despite the regulatory domain perturbations. Case studies further supported the efficacy of dasatinib in overcoming resistance associated with these mutations. Importantly, detection of this mutation pair in an independent validation set underscores the relevance of regulatory domain alterations as a previously under-recognized mechanism of TKI resistance. These findings advocate for routine interrogation of BCR::ABL1 regulatory domains to refine therapeutic decision-making in imatinib-refractory CML.
The cell cycle is a pervasive and highly regulated cellular process wherein a cell duplicates its genome and divides equally into two daughter cells. A large number of proteins are involved in cont...
27 October 2026 in BMC Complementary Medicine and Therapies
Balanites aegyptiaca (Zygophyllaceae), a species indigenous to Africa and parts of India, is widely valued for its medicinal properties. Several plant orga